Comparison
Peptide-vs-peptide, country-vs-country, label-vs-grey-market. Methodology disclosed, conclusions tied to primary sources.
Semaglutide vs retatrutide: one vs three
Semaglutide hits one receptor and has cardiovascular outcome data. Retatrutide hits three and is still investigational.
PT-141 vs semaglutide: two brain targets
Both peptides act on brain receptors, and that is where the similarity stops. One is licensed for low sexual desire, the other for weight and heart risk.
BPC-157 vs TB-500 for injury recovery
BPC-157 has more injury-specific animal research than TB-500, but neither has solid human evidence for faster recovery.
Ipamorelin vs CJC-1295: GH-axis stack
Ipamorelin and CJC-1295 act on different GH pathways, but no human trial has shown that combining them improves clinical outcomes.
Semaglutide vs tesamorelin compared
Semaglutide and tesamorelin are both FDA-approved peptides, but their regulatory paths, evidence bases and grey-market exposure could not be more different.